HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Clinical trials for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) explained in plain language.
Never miss a new study
Get alerted when new HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) trials appear
Sign up with your email to follow new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibiotic strategy targets deadly infections in vulnerable patients
Disease control TerminatedThis study tested whether the antibiotic ceftolozane-tazobactam can effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. Participants received the drug through a vein every 8 hours for 10 to 14 days. Res…
Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug hope for lung damage after transplant falls short
Disease control TerminatedThis study tested the drug ruxolitinib to treat early lung damage in children and adults who had a stem cell transplant. Lung problems like bronchiolitis obliterans can be serious and hard to detect early. The trial aimed to see if adding ruxolitinib to standard care could improv…
Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC